{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:19:57Z","timestamp":1785388797509,"version":"3.55.0"},"reference-count":356,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"DOI":"10.1093\/ckj\/sfx081","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T03:11:44Z","timestamp":1501038704000},"page":"600-624","source":"Crossref","is-referenced-by-count":60,"title":["Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea"],"prefix":"10.1093","volume":"10","author":[{"given":"Vicky","family":"Brocklebank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,8]]},"reference":[{"key":"key\n\t\t\t\t20171011230841_sfx081-B1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","year":"2010","journal-title":"Nat Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","year":"2013","journal-title":"Semin Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B4","article-title":"All things complement","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B6","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","year":"1996","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B7","first-page":"1017","article-title":"Eculizumab (Alexion)","volume":"3","year":"2002","journal-title":"Curr Opin Invest Drugs"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.smim.2016.05.001","article-title":"Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future","volume":"28","year":"2016","journal-title":"Semin Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.trsl.2014.10.010","article-title":"Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"165","year":"2015","journal-title":"Transl Res"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis","volume":"29","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B15","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","year":"2016","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B16","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1542\/peds.2014-3503","article-title":"Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome","volume":"135","year":"2015","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1212\/WNL.0000000000002312","article-title":"Eculizumab-related progressive multifocal leukoencephalopathy","volume":"86","year":"2016","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00467-014-2990-5","article-title":"Eculizumab hepatotoxicity in pediatric aHUS","volume":"30","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B20","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1681\/ASN.2011121186","article-title":"Pathology after eculizumab in dense deposit disease and C3 GN","volume":"23","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B21","article-title":"Rare genetic variants in Shiga toxin\u2013associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential","year":"2017","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: State of the art","volume":"67","year":"2015","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.transci.2016.04.012","article-title":"The alternative pathway of complement and the thrombotic microangiopathies","volume":"54","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B25","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","year":"1998","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B27","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2007.05.004","article-title":"Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome","volume":"45","year":"2008","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B29","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.4049\/jimmunol.0804031","article-title":"The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome","volume":"182","year":"2009","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B30","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","year":"2010","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2215\/CJN.05750611","article-title":"Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?","volume":"7","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B34","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.4049\/jimmunol.1402770","article-title":"Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases","volume":"194","year":"2015","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B35","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","year":"2014","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B36","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.1200679","article-title":"Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome","volume":"189","year":"2012","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B39","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","year":"2016","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B40","article-title":"Factor H autoantibody associated atypical haemolytic uraemic syndrome in children in the United Kingdom and Ireland (2000\u20132015)","year":"2017","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B41","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1111\/petr.12066","article-title":"Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series","volume":"17","year":"2013","journal-title":"Pediatr Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience","volume":"109","year":"2016","journal-title":"QJM"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B43","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B44","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"98","year":"2014","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B45","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2215\/CJN.10181110","article-title":"Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome","volume":"6","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B46","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMc1001060","article-title":"Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B47","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/j.1600-6143.2012.04051.x","article-title":"Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH\/CFHR1 hybrid protein","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B48","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","article-title":"Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome","volume":"26","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00467-013-2591-8","article-title":"Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH\/CFHR1 hybrid gene","volume":"29","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B50","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/TP.0b013e31829d388d","article-title":"Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation","volume":"96","year":"2013","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B51","doi-asserted-by":"crossref","first-page":"E185","DOI":"10.1111\/petr.12290","article-title":"Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation","volume":"18","year":"2014","journal-title":"Pediatr Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B52","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1016\/j.transproceed.2012.07.141","article-title":"Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report","volume":"44","year":"2012","journal-title":"Transplant Proc"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B53","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/imj.12864","article-title":"Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort","volume":"45","year":"2015","journal-title":"Intern Med J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5414\/CN108808","article-title":"Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab","volume":"86","year":"2016","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00467-013-2722-2","article-title":"Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?","volume":"29","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B56","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-6143.2005.01184.x","article-title":"Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy\/hemolytic uremic syndrome","volume":"6","year":"2006","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B57","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1111\/j.1600-6143.2009.02817.x","article-title":"Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B58","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/j.1432-2277.2012.01497.x","article-title":"Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft","volume":"25","year":"2012","journal-title":"Transpl Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndtplus\/sfr107","article-title":"Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome","volume":"5","year":"2012","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B60","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.transproceed.2015.08.004","article-title":"Thrombotic microangiopathy as a cause of chronic kidney transplant dysfunction: case report demonstrating successful treatment with eculizumab","volume":"47","year":"2015","journal-title":"Transplant Proc"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B61","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/TP.0b013e3181ccd80d","article-title":"Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation","volume":"89","year":"2010","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B62","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/j.ajkd.2009.08.011","article-title":"Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation","volume":"55","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B63","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B64","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2215\/CJN.00050505","article-title":"Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background","volume":"1","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B65","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/MNH.0b013e328365b3fe","article-title":"Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"22","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B66","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","year":"2008","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B67","first-page":"125","article-title":"Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report","volume":"83","year":"2015","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B68","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nep.12768","article-title":"Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab","volume":"21","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B69","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.nefro.2016.02.003","article-title":"Late onset of de novo atypical hemolytic-uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab","volume":"36","year":"2016","journal-title":"Nefrologia"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B70","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/TP.0b013e318230c0bd","article-title":"Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab","volume":"92","year":"2011","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B71","first-page":"2097","article-title":"Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation\u2013a case report. Transplant","volume":"43","year":"2011","journal-title":"Proc"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B72","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1046\/j.1600-6143.2003.00222.x","article-title":"Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation","volume":"3","year":"2003","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B73","first-page":"260254","article-title":"Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy","volume":"2013","year":"2013","journal-title":"Case Rep Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B74","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00467-014-3036-8","article-title":"De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus","volume":"30","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B75","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1399-0012.2007.00765.x","article-title":"Thrombotic microangiopathy following pancreas after kidney transplants","volume":"22","year":"2008","journal-title":"Clin Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B76","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nrneph.2012.212","article-title":"The role of complement in antibody-mediated rejection in kidney transplantation","volume":"8","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B77","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1111\/j.1600-6143.2012.04124.x","article-title":"Antibody mediated rejection associated with complement factor h-related protein 3\/1 deficiency successfully treated with eculizumab","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B78","first-page":"9874261","article-title":"Eculizumab for the treatment of severe antibody-mediated rejection: a case report and review of the literature","volume":"2016","year":"2016","journal-title":"Case Rep Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B79","first-page":"2690","article-title":"Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant","volume":"44","year":"2012","journal-title":"Proc"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B80","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.transproceed.2012.03.053","article-title":"Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant","volume":"44","year":"2012","journal-title":"Transplant Proc"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B81","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","year":"2011","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B82","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1\u2009year","volume":"15","year":"2015","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B83","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial","year":"2016","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B84","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/petr.12187","article-title":"Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody","volume":"18","year":"2014","journal-title":"Pediatr Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B85","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B86","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1542\/peds.2014-2275","article-title":"Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient","volume":"135","year":"2015","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B87","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/j.1432-2277.2011.01290.x","article-title":"Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation","volume":"24","year":"2011","journal-title":"Transpl Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B88","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/TP.0000000000000184","article-title":"Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts","volume":"98","year":"2014","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B89","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/TP.0000000000000298","article-title":"Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation","volume":"98","year":"2014","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B90","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/tri.12396","article-title":"Antibody-mediated rejection despite inhibition of terminal complement","volume":"27","year":"2014","journal-title":"Transpl Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B91","first-page":"1754","article-title":"Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience. Transplant","volume":"47","year":"2015","journal-title":"Proc"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B92","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes Transplant Work Group","year":"2009","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B93","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","article-title":"Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation","volume":"125","year":"2015","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B94","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","year":"2013","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B95","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.01640214","article-title":"Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome","volume":"9","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B96","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2215\/CJN.08520814","article-title":"Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome","volume":"10","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B97","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1681\/ASN.2013080886","article-title":"Phenotypic expansion of DGKE-associated diseases","volume":"25","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B98","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.4049\/jimmunol.1301221","article-title":"Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy","volume":"191","year":"2013","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B99","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1160\/TH04-07-0450","article-title":"Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies","volume":"93","year":"2005","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B100","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3324\/haematol.2016.149021","article-title":"Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura","volume":"101","year":"2016","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B101","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","article-title":"Complement activation in thrombotic thrombocytopenic purpura","volume":"10","year":"2012","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B102","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjh.12707","article-title":"Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura","volume":"164","year":"2014","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B103","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/jth.12369","article-title":"Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura","volume":"11","year":"2013","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B104","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12185-015-1933-7","article-title":"Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency","volume":"103","year":"2016","journal-title":"Int J Hematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B105","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1681\/ASN.2005010086","article-title":"Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement","volume":"16","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B106","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura","volume":"157","year":"2012","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B107","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.12387","article-title":"Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up","volume":"162","year":"2013","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B108","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.ajkd.2015.06.032","article-title":"Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab","volume":"66","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B109","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jca.21470","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue","volume":"31","year":"2016","journal-title":"J Clin Apher"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B110","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B111","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13408","article-title":"A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed\/refractory thrombotic thrombocytopenic purpura treated with rituximab","volume":"170","year":"2015","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B112","article-title":"Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter non-comparative study","year":"2016","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B113","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B114","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B115","first-page":"487","article-title":"Eculizumab for atypical hemolytic uremic syndrome in pregnancy","volume":"122 (2\u2009Pt 2)","year":"2013","journal-title":"Obstet Gynecol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B116","first-page":"176","article-title":"Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab","volume":"159","year":"2013","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B117","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","year":"2014","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B118","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.exphem.2016.01.005","article-title":"Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome","volume":"44","year":"2016","journal-title":"Exp Hematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B119","first-page":"698","article-title":"Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count","volume":"76","year":"1990","journal-title":"Obstet Gynecol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B120","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.molimm.2010.01.021","article-title":"Activation of the complement system in normal pregnancy and preeclampsia","volume":"47","year":"2010","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B121","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/aji.12541","article-title":"Expression of the complement system's activation factors in plasma of patients with early\/late-onset severe pre-eclampsia","volume":"76","year":"2016","journal-title":"Am J Reprod Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B122","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1600-0897.2009.00731.x","article-title":"Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count","volume":"62","year":"2009","journal-title":"Am J Reprod Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B123","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2008-03-144691","article-title":"Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome","volume":"112","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B124","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3109\/14767058.2012.694923","article-title":"The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome","volume":"25","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B125","doi-asserted-by":"crossref","first-page":"e1001013","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort","volume":"8","year":"2011","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B126","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B127","article-title":"Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","year":"2013","journal-title":"Placenta"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B129","article-title":"Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B130","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00467-010-1609-8","article-title":"CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency","volume":"25","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B131","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/j.ajkd.2004.12.004","article-title":"Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation","volume":"45","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B132","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","article-title":"Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency","volume":"63","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B133","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis","volume":"187","year":"2011","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B134","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.kint.2016.05.011","article-title":"Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury","volume":"90","year":"2016","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B135","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1681\/ASN.2013050450","article-title":"Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement","volume":"25","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B136","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","year":"2009","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B137","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.molimm.2013.11.009","article-title":"Interaction of Shiga toxin 2 with complement regulators of the factor H protein family","volume":"58","year":"2014","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B138","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","article-title":"Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome","volume":"117","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B139","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.4049\/jimmunol.1402470","article-title":"Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome","volume":"194","year":"2015","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B140","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/ndt\/gfw078","article-title":"Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome","volume":"31","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B141","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/cei.12601","article-title":"Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome","volume":"181","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B142","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B143","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1111\/ajt.12297","article-title":"Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B144","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00467-015-3207-2","article-title":"CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS)","volume":"31","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B145","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1681\/ASN.2015010100","article-title":"A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H\/complement factor H-related 3 gene in atypical hemolytic uremic syndrome","volume":"27","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B146","article-title":"Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B147","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B148","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study","volume":"345","year":"2012","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B149","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B150","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","article-title":"Long-term outcomes of Shiga toxin hemolytic uremic syndrome","volume":"28","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B151","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0140-6736(11)61253-1","article-title":"Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial","volume":"378","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B152","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","article-title":"Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials","volume":"53","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B153","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/cid\/cis531","article-title":"An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children","volume":"55","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B154","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1086\/497605","article-title":"In vivo binding of complement regulator factor H by Streptococcus pneumoniae","volume":"192","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.imbio.2011.07.022","article-title":"Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome?","volume":"217","year":"2012","journal-title":"Immunobiology"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B156","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.mehy.2013.05.030","article-title":"Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?","volume":"81","year":"2013","journal-title":"Med Hypotheses"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B157","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/ndt\/gft198","article-title":"The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome","volume":"28","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B158","first-page":"5","article-title":"Atypical haemolytic uraemic syndrome","volume":"77\u201378","year":"2006","journal-title":"Br Med Bull"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B159","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/ckj\/sfw035","article-title":"Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab","volume":"9","year":"2016","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B160","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1523-1755.2003.00743.x","article-title":"Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy","volume":"63","year":"2003","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B161","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/ndt\/14.6.1578","article-title":"Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies","volume":"14","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B162","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1086\/422363","article-title":"HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study","volume":"39","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B163","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/tri.12582","article-title":"Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature","volume":"28","year":"2015","journal-title":"Transpl Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B164","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/leu.2011.185","article-title":"Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors","volume":"26","year":"2012","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B165","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1172\/JCI61019","article-title":"Antigen-presenting cell-derived complement modulates graft-versus-host disease","volume":"122","year":"2012","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B166","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1827.2011.02704.x","article-title":"Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"61","year":"2011","journal-title":"Pathol Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B167","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1111\/petr.12450","article-title":"Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition","volume":"19","year":"2015","journal-title":"Pediatr Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B168","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","year":"2014","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B169","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.bbmt.2005.07.012","article-title":"Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children","volume":"11","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B170","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B171","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","year":"2016","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B172","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.transci.2016.04.007","article-title":"New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"54","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B173","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","year":"2015","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B174","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B175","first-page":"565","article-title":"Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments","volume":"12","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B176","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bjh.12202","article-title":"Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy","volume":"161","year":"2013","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B177","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/bmt.2014.97","article-title":"Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia","volume":"49","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B178","first-page":"425410","article-title":"Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation","volume":"2015","year":"2015","journal-title":"Case Rep Hematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B179","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.4081\/hr.2015.6107","article-title":"Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease","volume":"7","year":"2015","journal-title":"Hematol Rep"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B180","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bmt.2016.87","article-title":"Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"51","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B182","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B181","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1076029615598221","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"22","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B183","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.transci.2007.03.004","article-title":"ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy","volume":"36","year":"2007","journal-title":"Transfus Apher Sci"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B184","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2007.06588.x","article-title":"Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab","volume":"137","year":"2007","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B185","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/bmt.2008.25","article-title":"Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura","volume":"41","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B186","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/ATVBAHA.113.303120","article-title":"Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling","volume":"34","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B187","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/ajh\/hpt274","article-title":"Antagonist of C5aR prevents cardiac remodeling in angiotensin II-induced hypertension","volume":"27","year":"2014","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B188","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.jhh.1002129","article-title":"Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study","volume":"21","year":"2007","journal-title":"J Hum Hypertens"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B189","doi-asserted-by":"crossref","first-page":"e42010","DOI":"10.1371\/journal.pone.0042010","article-title":"Associations of CFH polymorphisms and CFHR1-CFHR3 deletion with blood pressure and hypertension in Chinese population","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10641963.2010.503303","article-title":"Clinical features of malignant hypertension with thrombotic microangiopathy","volume":"33","year":"2011","journal-title":"Clin Exp Hypertens"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B191","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2040620715571076","article-title":"Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura","volume":"6","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B192","first-page":"915 e17","article-title":"Malignant hypertension with reversible brainstem hypertensive encephalopathy and thrombotic microangiopathy","volume":"21","year":"2012","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B193","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood-2013-03-487694","article-title":"Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies","volume":"121","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B194","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2169\/internalmedicine.55.5703","article-title":"Clopidogrel-induced thrombotic microangiopathy in a patient with hypocomplementemia","volume":"55","year":"2016","journal-title":"Intern Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B195","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","article-title":"Eculizumab and drug-induced haemolytic-uraemic syndrome","volume":"6","year":"2013","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B196","article-title":"Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy","year":"2013","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B197","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B198","article-title":"Gemcitabine-associated thrombotic microangiopathy: response to complement inhibition and reinitiation of gemcitabine","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B199","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","year":"2016","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B200","doi-asserted-by":"crossref","first-page":"794","DOI":"10.7326\/0003-4819-132-10-200005160-00005","article-title":"Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura","volume":"132","year":"2000","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B201","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jca.20213","article-title":"Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?","volume":"24","year":"2009","journal-title":"J Clin Apher"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B202","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.transci.2016.03.002","article-title":"Carfilzomib: A cause of drug associated thrombotic microangiopathy","volume":"54","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.12-1-11","article-title":"Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases","volume":"12","year":"2007","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B204","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry","volume":"7","year":"1989","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B205","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","year":"2009","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B206","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","article-title":"Amelioration of lupus-like autoimmune disease in NZB\/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5","volume":"93","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B207","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clim.2013.02.014","article-title":"Targeting the complement system in systemic lupus erythematosus and other diseases","volume":"148","year":"2013","journal-title":"Clin Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B208","doi-asserted-by":"crossref","first-page":"e1002079","DOI":"10.1371\/journal.pgen.1002079","article-title":"Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility","volume":"7","year":"2011","journal-title":"PLoS Genet"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B209","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/RHU.0000000000000423","article-title":"Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus","volume":"22","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy","volume":"30","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B211","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab","volume":"65","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B212","first-page":"2286","article-title":"Eculizumab as rescue therapy in severe resistant lupus nephritis","volume":"54","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B213","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.4081\/hr.2016.6625","article-title":"Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab","volume":"8","year":"2016","journal-title":"Hematol Rep"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B214","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10067-003-0742-1","article-title":"Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review","volume":"22","year":"2003","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B215","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2009-01-199117","article-title":"Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies","volume":"114","year":"2009","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B216","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","year":"2003","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B217","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molimm.2004.07.043","article-title":"A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice","volume":"42","year":"2005","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B218","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1177\/0961203314546022","article-title":"Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies","volume":"23","year":"2014","journal-title":"Lupus"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B219","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B220","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","article-title":"Complement activation in patients with primary antiphospholipid syndrome","volume":"68","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B221","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00460110","article-title":"Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients","volume":"5","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B222","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3899\/jrheum.150185","article-title":"Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis","volume":"42","year":"2015","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B223","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/rheumatology\/kew040","article-title":"Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome","volume":"55","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B224","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B225","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B226","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/rheumatology\/kev371","article-title":"A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor","volume":"55","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B227","first-page":"704371","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","volume":"2014","year":"2014","journal-title":"Case Rep Hematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B228","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/RHU.0000000000000290","article-title":"Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome","volume":"21","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B229","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","article-title":"Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation","volume":"11","year":"2011","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B230","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/TP.0000000000000267","article-title":"A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab","volume":"98","year":"2014","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B231","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","year":"2014","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B232","article-title":"Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry","year":"2016","journal-title":"Autoimmun Rev"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B233","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B234","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.molimm.2008.12.002","article-title":"Is complement factor H a susceptibility factor for IgA nephropathy?","volume":"46","year":"2009","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B235","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/ndt\/13.8.1984","article-title":"Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy","volume":"13","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B236","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000045212","article-title":"Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy","volume":"80","year":"1998","journal-title":"Nephron"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B237","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1053\/ajkd.2001.28611","article-title":"Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis","volume":"38","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B238","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B239","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF00916894","article-title":"Partial H (beta 1H) deficiency and glomerulonephritis in two families","volume":"2","year":"1982","journal-title":"J Clin Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B240","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","year":"2011","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B241","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1681\/ASN.2015010012","article-title":"Rare variants in the complement factor h-related protein 5 gene contribute to genetic susceptibility to IgA nephropathy","volume":"27","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B242","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ckj\/sfv076","article-title":"Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum?","volume":"8","year":"2015","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B243","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00467-014-2863-y","article-title":"Eculizumab treatment for rescue of renal function in IgA nephropathy","volume":"29","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B244","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B245","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","year":"2007","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B246","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B247","doi-asserted-by":"crossref","first-page":"e4871","DOI":"10.1097\/MD.0000000000004871","article-title":"Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B248","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2215\/CJN.00120115","article-title":"Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis","volume":"10","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B249","article-title":"Complement in ANCA-associated glomerulonephritis","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B250","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B251","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B252","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","article-title":"The role of complement in membranous nephropathy","volume":"33","year":"2013","journal-title":"Semin Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B253","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1159\/000079174","article-title":"Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy","volume":"97","year":"2004","journal-title":"Nephron Clin Pract"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B254","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00467-009-1439-8","article-title":"IgG subclasses and complement pathway in segmental and global membranous nephropathy","volume":"25","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B255","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1681\/ASN.2004121098","article-title":"Cellular response to injury in membranous nephropathy","volume":"16","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B256","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B257","first-page":"311","article-title":"Micro-angiopathic haemolysis, thrombocytopenia and nephrotic syndrome associated with membranous nephropathy in a Vietnamese boy","volume":"24","year":"1988","journal-title":"Aust Paediatr J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B258","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/ndt\/gft220","article-title":"Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature","volume":"28","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B259","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ajh.20243","article-title":"Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases","volume":"78","year":"2005","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B260","first-page":"561","article-title":"Membranous nephropathy and thrombotic thrombocytopenic purpura treated with rituximab","volume":"22","year":"2009","journal-title":"J Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B261","doi-asserted-by":"crossref","first-page":"e0136558","DOI":"10.1371\/journal.pone.0136558","article-title":"Complement activation in patients with focal segmental glomerulosclerosis","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B262","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.2215\/CJN.01190216","article-title":"Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis","volume":"11","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B263","article-title":"Thrombotic microangiopathy in inverted formin 2-mediated renal disease","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B264","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.humpath.2008.08.001","article-title":"Renal biopsy findings predicting outcome in scleroderma renal crisis","volume":"40","year":"2009","journal-title":"Hum Pathol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B265","doi-asserted-by":"crossref","first-page":"e0114856","DOI":"10.1371\/journal.pone.0114856","article-title":"The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B266","doi-asserted-by":"crossref","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B267","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ckj\/sfv101","article-title":"Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome","volume":"8","year":"2015","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B268","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B269","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1093\/ndt\/gfs317","article-title":"Prognosis of scleroderma renal crisis: a long-term observational study","volume":"27","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B270","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.0601094103","article-title":"Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice","volume":"103","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B271","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","year":"2012","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B272","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","year":"2016","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B273","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B274","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJMc1106619","article-title":"Eculizumab and refractory membranoproliferative glomerulonephritis","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B275","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1093\/ndt\/gfr422","article-title":"Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis","volume":"26","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B276","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00467-013-2503-y","article-title":"Eculizumab and recurrent C3 glomerulonephritis","volume":"28","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B277","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13000-016-0547-6","article-title":"Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy","volume":"11","year":"2016","journal-title":"Diagn Pathol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B278","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00467-015-3306-0","article-title":"Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease","volume":"31","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B279","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMc1111953","article-title":"Eculizumab for the treatment of dense-deposit disease","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B280","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00467-013-2711-5","article-title":"Rituximab fails where eculizumab restores renal function in C3nef-related DDD","volume":"29","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B281","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00467-015-3061-2","article-title":"A case of C3 glomerulonephritis successfully treated with eculizumab","volume":"30","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B282","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMc1112273","article-title":"Eculizumab in a patient with dense-deposit disease","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B283","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ckj\/sfv044","article-title":"Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis","volume":"8","year":"2015","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B284","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","article-title":"Eculizumab for treatment of rapidly progressive C3 glomerulopathy","volume":"65","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B285","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2215\/CJN.01360215","article-title":"Eculizumab in pediatric dense deposit disease","volume":"10","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B286","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-013-2748-5","article-title":"Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy","volume":"29","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B287","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1600-6143.2011.03923.x","article-title":"Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B288","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00467-014-2839-y","article-title":"Eculizumab in dense-deposit disease after renal transplantation","volume":"29","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B289","first-page":"65","article-title":"Complement, thrombotic microangiopathy and disseminated intravascular coagulation","volume":"2","year":"2014","journal-title":"J Intensive Care"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B290","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B291","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.kint.2015.12.039","article-title":"Eculizumab in children with hemolytic uremic syndrome","volume":"89","year":"2016","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B292","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.imbio.2015.05.002","article-title":"Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS)","volume":"221","year":"2016","journal-title":"Immunobiology"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B293","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1055\/s-0030-1262887","article-title":"Transplantation in atypical hemolytic uremic syndrome","volume":"36","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B294","first-page":"1058","article-title":"Thrombotic microangiopathy after renal transplantation in the United States","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B295","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1432-2277.2006.00354.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"19","year":"2006","journal-title":"Transpl Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B296","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","article-title":"Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation","volume":"27","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B297","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.blre.2014.09.001","article-title":"De novo thrombotic microangiopathy after non-renal solid organ transplantation","volume":"28","year":"2014","journal-title":"Blood Rev"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B298","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/j.1600-6143.2010.03178.x","article-title":"De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B299","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/ajt.13661","article-title":"The Revised (2013) Banff Classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B300","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1681\/ASN.2012090903","article-title":"DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN","volume":"24","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B301","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B302","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B303","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.transci.2016.04.009","article-title":"Pregnancy-related thrombotic microangiopathies: Clues from complement biology","volume":"54","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B304","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00062752-200309000-00003","article-title":"The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"10","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B305","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.2215\/CJN.13121211","article-title":"Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy","volume":"7","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B306","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","article-title":"Pre-eclampsia","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B307","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1097\/01.ASN.0000027873.85792.52","article-title":"Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: upregulation of globotriaosylceramide expression","volume":"13","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B308","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3390\/toxins2122769","article-title":"Escherichia coli Shiga toxin mechanisms of action in renal disease","volume":"2","year":"2010","journal-title":"Toxins (Basel)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B309","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1159\/000235253","article-title":"Pathogenesis of thrombotic microangiopathy: insights from animal models","volume":"113","year":"2009","journal-title":"Nephron Exp Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B310","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","article-title":"Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement","volume":"94","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B311","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nrneph.2012.196","article-title":"Renal and neurological involvement in typical Shiga toxin-associated HUS","volume":"8","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B312","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/INF.0b013e3182191c58","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America","volume":"30","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B313","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1440-1797.2011.01500.x","article-title":"Invasive pneumococcal pneumonia is the major cause of paediatric haemolytic-uraemic syndrome in Taiwan","volume":"17","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B314","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1440-1754.2009.01603.x","article-title":"Ten years of pneumococcal-associated haemolytic uraemic syndrome in New Zealand children","volume":"45","year":"2009","journal-title":"J Paediatr Child Health"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B315","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpeds.2007.03.055","article-title":"Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience","volume":"151","year":"2007","journal-title":"J Pediatr"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B316","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nchembio.1696","article-title":"Structural basis for sialic acid-mediated self-recognition by complement factor H","volume":"11","year":"2015","journal-title":"Nat Chem Biol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B317","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5144\/1658-3876.2011.51","article-title":"Viral-associated thrombotic microangiopathies","volume":"4","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B318","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1681\/ASN.V132370","article-title":"Cellular injury associated with renal thrombotic microangiopathy in human immunodeficiency virus-infected macaques","volume":"13","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B319","article-title":"Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B320","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","article-title":"Microangiopathic hemolysis and renal failure in malignant hypertension","volume":"45","year":"2005","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B321","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.amjhyper.2007.02.018","article-title":"The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension","volume":"20","year":"2007","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B322","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2369-13-71","article-title":"Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study","volume":"13","year":"2012","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B323","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.kint.2017.02.025","article-title":"Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?","volume":"91","year":"2017","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B324","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","year":"2017","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B325","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5414\/CNP73147","article-title":"Severe renal failure and microangiopathic hemolysis induced by malignant hypertension\u2013case series and review of literature","volume":"73","year":"2010","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B326","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","year":"2015","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B327","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","year":"2016","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B328","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B329","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B330","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B331","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00005792-197909000-00004","article-title":"Microangiopathic hemolytic anemia and cancer: a review","volume":"58","year":"1979","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B332","first-page":"908","article-title":"Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia","volume":"25","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B333","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1158\/1078-0432.CCR-10-0321","article-title":"Complement factor H autoantibodies are associated with early stage NSCLC","volume":"16","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B334","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00467-007-0563-6","article-title":"Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis","volume":"22","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B335","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/BF01959094","article-title":"Recurrent haemolytic uraemic syndrome in a boy with focal and segmental glomerulosclerosis","volume":"151","year":"1992","journal-title":"Eur J Pediatr"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B336","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrneph.2014.250","article-title":"Podocyte dysfunction in atypical haemolytic uraemic syndrome","volume":"11","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B337","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s004670050189","article-title":"Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome","volume":"10","year":"1996","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B338","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5414\/CNP66397","article-title":"A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy","volume":"66","year":"2006","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B339","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B340","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrneph.2016.107","article-title":"Insights into kidney diseases from genome-wide association studies","volume":"12","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B341","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2215\/CJN.07910814","article-title":"Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin","volume":"10","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B342","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/bmj.1.6120.1112","article-title":"Haemolytic uraemic syndrome and idiopathic membranous glomerulonephritis","volume":"1","year":"1978","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B343","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0272-6386(12)80257-5","article-title":"Recurrent thrombotic thrombocytopenic purpura associated with membranous glomerulopathy","volume":"17","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B344","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1681\/ASN.2013070732","article-title":"Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN","volume":"25","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B345","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1681\/ASN.2012020166","article-title":"A hybrid CFHR3-1 gene causes familial C3 glomerulopathy","volume":"23","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B346","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.ki.5000269","article-title":"Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)","volume":"70","year":"2006","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B347","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2012.05.009","article-title":"Factor H autoantibodies in membranoproliferative glomerulonephritis","volume":"52","year":"2012","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B348","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0140-6736(10)60670-8","article-title":"Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B349","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1053\/j.ajkd.2007.11.032","article-title":"Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits","volume":"51","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B350","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/ndt\/gfr436","article-title":"Three kidneys, two diseases, one antibody?","volume":"26","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B351","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ndt\/gfg470","article-title":"Familial mesangio-capillary glomerulonephritis with initial presentation as haemolytic uraemic syndrome","volume":"19","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B352","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/RHU.0000000000000425","article-title":"Renal thrombotic microangiopathy in proliferative lupus nephritis: risk factors and clinical outcomes: a case-control study","volume":"22","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B353","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2215\/CJN.02870311","article-title":"Evaluation of clinical outcomes and renal vascular pathology among patients with lupus","volume":"7","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B354","first-page":"503","article-title":"Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome","volume":"33","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B355","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11926-015-0551-y","article-title":"Recent developments in the classification, evaluation, pathophysiology, and management of scleroderma renal crisis","volume":"18","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"key\n\t\t\t\t20171011230841_sfx081-B356","first-page":"7","author":"National Institute for Health and Care Excellence","year":"2015"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/10\/5\/600\/20385988\/sfx081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:01:32Z","timestamp":1750788092000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ckj\/article\/10\/5\/600\/4283135\/Complement-C5inhibiting-therapy-for-the-thrombotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,8]]},"references-count":356,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,8]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfx081","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,5,8]]}}}